Systematic study of the selenium fractionation in human plasma from a cancer prevention trial using HPLC hyphenated to ICP-MS and ESI-MS/MS.
Aged
Chemical Fractionation
Chromatography, High Pressure Liquid
/ methods
Denmark
Dietary Supplements
Enzymes
/ chemistry
Humans
Hydrolysis
Male
Neoplasms
/ blood
Pilot Projects
Selenium
/ administration & dosage
Selenium Compounds
Selenomethionine
/ analysis
Spectrometry, Mass, Electrospray Ionization
/ methods
Spectrum Analysis
Tandem Mass Spectrometry
United Kingdom
HPLC/ICP-MS
Human plasma
PRECISE trial
Selenium
Speciation
Journal
Analytical and bioanalytical chemistry
ISSN: 1618-2650
Titre abrégé: Anal Bioanal Chem
Pays: Germany
ID NLM: 101134327
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
22
07
2020
accepted:
05
10
2020
revised:
10
09
2020
pubmed:
4
11
2020
medline:
7
9
2021
entrez:
3
11
2020
Statut:
ppublish
Résumé
This work represents the first systematic speciation study of selenium (Se) in plasma from subjects participating in a pilot study for a cancer prevention trial (PRECISE). This involved supplementation of elderly British and Danish individuals with selenised yeast for 6 months and 5 years, respectively, at 100, 200, and 300 μg Se/day or placebo. Speciation data was obtained for male plasma using HPLC-ICP-MS and HPLC-ESI-MS/MS. With the proposed strategy, approximately 1.5 mL of plasma was needed to determine total Se concentration and the fractionation of Se in high molecular weight (HMW) and low molecular weight (LMW) pools, and for quantification and identification of small Se species. For the first time, Se-methyl-selenocysteine (MSC) and methyl-2-acetamido-2deoxy1-seleno-β-D-galactopyranoside (Selenosugar-1) were structurally confirmed in plasma after supplementation with selenised yeast within the studied range. Determination of selenomethionine (SeMet) incorporated non-specifically into albumin (SeALB) was achieved by HPLC-ICP-MS after hydrolysis. By subtracting this SeMet concentration from the total Se in the HMW pool, the concentration of Se incorporated into selenoproteins was calculated. Results from the speciation analysis of the free Se metabolite fraction (5% of total plasma Se) suggest a significant increase in the percentage of Se (as SeMet plus Selenosugar-1) of up to 80% of the total Se in the LMW fraction after 6 months of supplementation. The Se distribution in the HMW fraction reflects a significant increase in SeALB with Se depletion from selenoproteins, which occurs most significantly at doses of over 100 μg Se/day after 5 years. The results of this work will inform future trial design. Graphical abstract.
Identifiants
pubmed: 33140125
doi: 10.1007/s00216-020-02988-9
pii: 10.1007/s00216-020-02988-9
doi:
Substances chimiques
Enzymes
0
Selenium Compounds
0
Selenomethionine
964MRK2PEL
Selenium
H6241UJ22B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
331-344Références
Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc. 2005;64:527–42.
pubmed: 16313696
Clark LC, Dalkin B, Krongard A, Combs GF Jr, Turnbull BW, Slate EH, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol. 1998;81:730–4.
pubmed: 9634050
Peters U, Chatterjee N, Church TR, Mayo C, Sturup S, Foster CB, et al. High serum selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program. Cancer Epidemiol Biomark Prev. 2006;15:315–20.
Medina D, Thompson H, Ganther H, Ip C. Se-methylselenocysteine: a new compound for chemoprevention of breast cancer. Nutr Cancer. 2001;40:12–7.
pubmed: 11799917
Combs GF, Clark LC, Turnbull BW. An analysis of cancer prevention by selenium. Biofactors. 2001;14:153–9.
pubmed: 11568452
Goenaga-Infante H, O’Connor G, Rayman MP, Wahlen R, Entwisle J, Norris P, et al. Selenium speciation analysis of selenium-enriched supplements by HPLC with ultrasonic nebulisation ICP-MS and electrospray MS/MS detection. J Anal At Spectrom. 2004;19:1529–38.
Rayman MP. Selenium and human health. Lancet. 2012;379:1256–68.
pubmed: 22381456
Dipple A, Pigott MA, Milner JA. Selenium modifies carcinogen metabolism by inhibiting enzyme induction. Biol Trace Elem Res. 1986;10:153–7.
pubmed: 24254362
Kiremidjian-Schumacher L, Roy M, Wishe HI, Cohen MW, Stotzky G. Supplementation with selenium and human immune cell functions. Biol Trace Elem Res. 1994;41:115–27.
pubmed: 7946899
Becker K, Gromer S, Schirmer RH, Müller S. Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem. 2000;267:6118–25.
pubmed: 11012663
Wang Z, Jiang C, Lü J. Induction of caspase mediated apoptosis and cell cycle G1 arrest by selenium metabolite methylselenol. Mol Carcinog. 2002;34:113–20.
pubmed: 12112305
Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal. 2007;9:775–06.
pubmed: 17508906
Jitaru P, Goenaga-Infante H, Vaslin-Reimann S, Fisicaro P. A systematic approach to the accurate quantification of selenium in serum selenoalbumin by HPLC–ICP-MS. Anal Chim Acta. 2010;657:100–7.
pubmed: 20005320
Ip C, Dong Y, Ganther HE. New concepts in selenium chemoprevention. Cancer Metastasis Rev. 2002;21:281–9.
pubmed: 12549766
Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res. 2000;60:2882–6.
pubmed: 10850432
Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA. 1996;276:1957–63.
pubmed: 8971064
Lippman SM, Klein EA, Goodman PJ, Scott Lucia M, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers. The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39–51.
pubmed: 19066370
Duffield-Lillicio AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer trial. Br J Urol. 2003;91:608–12.
Kokarnig S, Tsirigotaki A, Wisenhofer T, Lackner V, Francesconi KA, Pergantis SA, et al. Concurrent quantitative HPLC–mass spectrometry profiling of small selenium species in human serum and urine after ingestion of selenium supplements. J Trace Elem Med Biol. 2015;29:83–90.
pubmed: 25063689
Kokarnig S, Kuehnelt D, Stiboller M, Hartleb U, Francesconi K. Quantitative determination of small selenium species in human serum by HPLC/ICPMS following a protein-removal, pre-concentration procedure. Anal Bioanal Chem. 2011;400:2323–7.
pubmed: 21547432
Flouda K, Derch JM, Gabel-Jensen C, Stürup S, Misra S, Björnstedt M, et al. Quantification of low molecular weight selenium metabolites in human plasma after treatment with selenite in pharmacological doses by LC-ICP-MS. Anal Bioanal Chem. 2016;408:2293–01.
pubmed: 26832729
Persson-Moschos M, Alfthan G, Ȧkesson B. Plasma selenoprotein P levels of healthy males in different selenium status after oral supplementation with different forms of selenium. Eur J Clin Nutr. 1998;52:363–7.
pubmed: 9630388
Burk RF, Norsworthy BK, Hill KE, Motley AK, Byrne DW. Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial. Cancer Epidemiol Biomark Prev. 2006;15:804–10.
Palacios Ò, Ruiz Encinar J, Schaumlöffel D, Lobinski R. Fractionation of selenium-containing proteins in serum by multiaffinity liquid chromatography before size-exclusion chromatography–ICPMS. Anal Bioanal Chem. 2006;384:1276–83.
pubmed: 16493548
Jitaru P, Prete M, Cozzi G, Turetta C, Cairns W, Seraglia R, et al. Speciation analysis of selenoproteins in human serum by solid-phase extraction and affinity HPLC hyphenated to ICP-quadrupole MS. J Anal At Spectrom. 2008;23:402–6.
Solovyev N, Berthele A, Michalke B. Selenium speciation in paired serum and cerebrospinal fluid samples. Anal Bioanal Chem. 2013;405:1875–84.
pubmed: 22868477
Jitaru P, Roman M, Cozzi G, Fisicaro P, Cescon P, Barbante C. Speciation analysis of selenoproteins in human serum by microbore affinity-HPLC hyphenated to ICP-sector field-MS using a high efficiency sample introduction system. Microchim Acta. 2009;166:319–27.
Jitaru P, Cozzi G, Gambaro A, Cescon P, Barbante C. Simultaneous speciation analysis of glutathione peroxidase, selenoprotein P and selenoalbumin in human serum by tandem anion exchange-affinity HPLC and on-line isotope dilution ICP-quadrupole MS. Anal Bioanal Chem. 2008;391:661–9.
pubmed: 18414835
Hinojosa Reyes L, Marchante-Gayón JM, García Alonso JI, Sanz-Medel A. Quantitative speciation of selenium in human serum by affinity chromatography coupled to post-column isotope dilution analysis ICP-MS. J Anal At Spectrom. 2003;18:1210–6.
Letsiou S, Lu Y, Nomikos T, Antonopoulou S, Panagiotakos D, Panagiotakos D, et al. High-throughput quantification of selenium in individual serum proteins from a healthy human population using HPLC on-line with isotope dilution inductively coupled plasma-MS. Proteomics. 2010;10:3447–57.
pubmed: 20827730
Garcia-Sevillano MA, Garcia-Barrera T, Gomez-Ariza JL. Development of a new column switching method for simultaneous speciation of selenometabolites and selenoproteins in human serum. J Chromatogr A. 2013;1318:171–9.
pubmed: 24139503
Jeong J-S, Lee J, Pak Y-N. Quantitative speciation of selenium in human blood serum and urine with AE- RP- and AF-HPLC-ICP/MS. Bull Kor Chem Soc. 2013;34:3817–24.
Ruiz Encinar J, Schaumlöffel D, Ogra Y, Lobinski R. Determination of selenomethionine and selenocysteine in human serum using speciated isotope dilution-capillary HPLC-inductively coupled plasma collision cell mass spectrometry. Anal Chem. 2004;76:6635–42.
Deitrich CL, Cuello-Nuñez S, Kmiotek D, Torma FA, Estela del Castillo Busto M, Fisicaro P, et al. Accurate quantification of selenoprotein P (SEPP1) in plasma using isotopically enriched seleno-peptides and species-specific isotope dilution with HPLC coupled to ICP-MS/MS. Anal Chem. 2016;88:6357–65.
pubmed: 27108743
Rayman MP, Stranges S, Griffin BA, Pastor-Barriuso P, Guallar E. Effect of supplementation with high-selenium yeast on plasma lipids. Ann Intern Med. 2011;154:656–65.
pubmed: 21576533
Rayman MP, Winther KH, Pastor-Barriuso R, Cold F, Thvilum M, Stranges S, et al. 2018 Effect of long-term selenium supplementation on mortality: results from a multiple-dose, randomised controlled trial. Free Radic Biol Med. 2018;127:46–54.
pubmed: 29454039
Rayman MP, Thompson A, Warren-Perry M, Galassini R, Catterick J, Hall E, et al. Impact of selenium on mood and quality of life: a randomized, controlled trial. Biol Psychiatry. 2006;59:147–54.
pubmed: 16181615
Rayman MP, Thompson AJ, Bekaert B, Catterick J, Galassini R, Hall E, et al. Randomized controlled trial of the effect of selenium supplementation on thyroid function in the elderly in the United Kingdom. Am J Clin Nutr. 2008;87:370–8.
pubmed: 18258627
Bekaert B, Cooper ML, Green FR, McNulty H, Pentieva K, Scott JM, et al. Effect of selenium status and supplementation with high-selenium yeast on plasma homocysteine and B vitamin concentrations in the UK elderly. Mol Nutr Food Res. 2008;52:1324–33.
pubmed: 18683819
Méplan C, Crosley LK, Nicol F, Beckett GJ, Howie AF, Hill KE, et al. Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the SELGEN study). FASEB J. 2007;21:3063–74.
pubmed: 17536041
Méplan C, Crosley LK, Nicol F, Horgan GW, Mathers JC, Arthur JR, et al. Functional effects of a common single-nucleotide polymorphism (GPX4c718t) in the glutathione peroxidase 4 gene: interaction with sex. Am J Clin Nutr. 2008;87:1019–27.
pubmed: 18400727
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on Dietary Reference Values for selenium. EFSA J. 2014;12:3846.
Goenaga-Infante H, Sturgeon R, Turner J, Hearn R, Sargent M, Maxwell P, et al. Total selenium and selenomethionine in pharmaceutical yeast tablets: assessment of the state of the art of measurement capabilities through international intercomparison CCQM-P86. Anal Bioanal Chem. 2008;390:629–42.
pubmed: 17938894
Warburton E, Goenaga-Infante H. Methane mixed plasma—improved sensitivity of inductively coupled plasma mass spectrometry detection for selenium speciation analysis of wheat-based food. J Anal At Spectrom. 2007;22:370–6.
Rayman MP. The use of high-selenium yeast to raise selenium status: how does it measure up? Br J Nutr. 2004;92:557–72.
pubmed: 15522125
Jitaru P, Roman M, Barbante C, Vaslin-Reimann S, Fisicaro P. Challenges in the accurate speciation analysis of selenium in humans: first report on indicative levels of selenoproteins in a serum certified reference material for total selenium (BCR-637). Accred Qual Assur. 2010;15:343–50.
Ogra Y, Ishiwata K, Takayama H, Aimi N, Suzuki KT. Identification of a novel selenium metabolite, se-methyl-N-acetylselenohexosamine, in rat urine by high-performance liquid chromatography–inductively coupled plasma mass spectrometry and –electrospray ionization tandem mass spectrometry. J Chromatogr B Biomed Appl. 2002;767:301–12.
Gabel-Jensen C, Odgaard J, Skonberg C, Badolo, Gammelgaard B. LC-ICP-MS and LC-ESI-(MS)